PCVX
Vaxcyte Inc
NASDAQ · Biotechnology
$56.15
+2.24 (+4.16%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 3.07B | 3.02B | 2.41B |
| Net Income | 147.42M | 150.65M | 124.53M |
| EPS | — | — | — |
| Profit Margin | 4.8% | 5.0% | 5.2% |
| Rev Growth | +1.9% | +8.9% | +10.2% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 4.24B | 4.14B | 4.52B |
| Total Equity | 3.42B | 3.07B | 3.05B |
| D/E Ratio | 1.24 | 1.35 | 1.48 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 264.93M | 279.22M | 238.21M |
| Free Cash Flow | 132.34M | 114.72M | 94.55M |